News & Publications
Press Releases
-
NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
June 9, 2020 by NanOlogy
-
NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
May 14, 2020 by NanOlogy
-
NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
November 7, 2019 by NanOlogy
-
NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®
October 15, 2019 by NanOlogy
NanOlogy in the News
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
- NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
- Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
- Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Presentations
- Video Highlights: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (3-minute version)
- Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version)
- ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer.
- ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts
- ATS 2019 Poster: Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel
Publications
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
- Digestive Disease Week 2020: Intracystic Injection of Submicron Particle Paclitaxel (SPP) for the Treatment of Mucinous Pancreatic Cystic Lesions Resulted in Reduction in Cyst Volume, an Interim Report (Mohamed O. Othman)
- Digestive Disease Week 2020: EUS-guided Injection of Intratumoral Submicron Particle Paclitaxel (SPP) for the Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) – Phase 2 Study (Neil Sharma, MD)
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
